Endo Health Solutions (Nasdaq: ENDP) is expected to report Q2 earnings on Aug. 6. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Endo Health Solutions's revenues will compress -8.1% and EPS will wither -9.4%.

The average estimate for revenue is $721.6 million. On the bottom line, the average EPS estimate is $1.15.

Revenue details
 Last quarter, Endo Health Solutions notched revenue of $708.5 million. GAAP reported sales were 2.6% higher than the prior-year quarter's $690.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $1.09. GAAP EPS were $0.14 for Q1 versus -$0.75 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Recent performance
 For the preceding quarter, gross margin was 59.6%, 350 basis points worse than the prior-year quarter. Operating margin was 21.7%, 830 basis points better than the prior-year quarter. Net margin was 2.2%, much better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $2.75 billion. The average EPS estimate is $4.33.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 420 members out of 444 rating the stock outperform, and 24 members rating it underperform. Among 143 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 136 give Endo Health Solutions a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Health Solutions is hold, with an average price target of $32.53.